Business context and reporting period
Filing identity note: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q for the quarter ended September 30, 2022; it does not identify Oruka Therapeutics, Inc. Investors should verify that this is the intended filing.
ARCA is a clinical-stage biopharmaceutical company developing rNAPc2 (AB201), a potential treatment for COVID-19 and other viral diseases, and Gencaro for atrial fibrillation in patients with chronic heart failure. It has generated no revenue and relies on external capital to fund development.
Financial performance and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 2022: $1.0 million; 2021: $3.4 million | 2022: $4.7 million; 2021: $9.9 million |
| General and administrative expense | 2022: $1.5 million; 2021: $1.3 million | 2022: $4.4 million; 2021: $3.8 million |
| Net loss | 2022: $2.3 million; 2021: $4.7 million | 2022: $8.8 million; 2021: $13.6 million |
| Net loss per share, basic and diluted | 2022: $0.16; 2021: $0.33 | 2022: $0.61; 2021: $0.99 |
At September 30, 2022, cash and cash equivalents were $43.9 million, down from $53.4 million at December 31, 2021. Total assets were $45.0 million; total liabilities were $2.2 million, including $0.4 million of operating lease liabilities. The filing reports no debt balance. Nine-month operating cash use was $9.4 million, versus $13.8 million in 2021; investing cash use was negligible, and there was no financing cash flow in 2022. No revenue-based margins are meaningful.
Changes versus prior period
Quarterly and nine-month net losses narrowed year over year, primarily alongside lower R&D spending after enrollment in the rNAPc2 Phase 2b trial was completed in the fourth quarter of 2021. G&A expense increased, reflecting professional and consulting costs and one-time workforce termination benefits. Cash declined by $9.4 million over the first nine months of 2022; in the comparable 2021 period, financing activities provided $23.1 million net from stock sales.
Outlook, commentary, risks and unusual items
- Management estimated that September 30 cash would fund operations at current levels through at least the end of fiscal 2023, but cautioned that strategic-review activity and changing circumstances could alter the estimate. Additional financing would be needed for further rNAPc2 trials and for Gencaro Phase 3 development.
- A board Special Committee, with Ladenburg Thalmann as adviser, is evaluating strategic alternatives, including a merger or asset sale. There is no defined timetable and no assurance of a transaction or that one would benefit shareholders.
- In July 2022, ARCA reduced its workforce by about 67% (12 employees) and recorded approximately $790,000 of one-time termination charges; about $250,000 remained unpaid at quarter-end.
- In the rNAPc2 Phase 2b trial, neither dose met statistical significance for the primary endpoint in the overall comparison with heparin. Secondary outcomes showed a nonsignificant numerical imbalance favoring rNAPc2; the company reported the drug was well tolerated, with no serious treatment-related adverse events.
- PRECISION-AF, the planned Phase 3 Gencaro trial, was on hold; initiation depends on additional funding and improved conditions for recruiting cardiovascular-trial patients amid the pandemic. The FDA Special Protocol Assessment does not guarantee approval.
- Key risks include funding availability and potential dilution, failure or delay in clinical and regulatory development, trial enrollment, competition and changing COVID-19 treatment needs, reliance on third parties, Nasdaq listing compliance, and uncertainty over the strategic review. The filing also notes that cash assumptions may prove wrong and operations could be reduced or discontinued if financing or a transaction is unavailable.
Most important facts for investors to verify
- Whether this ARCA Biopharma filing is the intended company and reporting period, given the request identifies Oruka Therapeutics.
- Cash runway assumptions, actual spending, and financing capacity; the filing states that the remaining ATM capacity was subject to a public-float limit and estimated at approximately $9.3 million as of October 27, 2022.
- Any outcome or update from the strategic review, including transaction terms and effects on shareholders.
- Whether rNAPc2 development advances despite the Phase 2b primary endpoint result, and whether funding and conditions permit a Gencaro Phase 3 trial.
- Nasdaq listing status and any future share issuance or dilution.